I suspect that was the EAP trial that finished some years ago. The data from that was presented to the ODAC, including the step change after Mesoblast took over the trial. When the EAP started it was under the auspices of Osiris, why I searched for prochymal at the time.
https://clinicaltrials.gov/ct2/show/NCT00759018?term=prochymal&cond=Graft-versus-host-disease
Based on very occasional comments from Silviu I believe Mesoblast continued to supply remestemcel-L for quite some time after the EAP finished, like years. Definitely worth confirmation of what is happening now.
I also did some comparison of the footprint remestemcel-L had across the US hospital system through various trials, seemed to be about 43 institutions.
- Forums
- ASX - By Stock
- MSB Trading 2021 - paradigm shift
I suspect that was the EAP trial that finished some years ago....
- There are more pages in this discussion • 6,325 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.26 |
Change
0.105(9.09%) |
Mkt cap ! $1.438B |
Open | High | Low | Value | Volume |
$1.16 | $1.30 | $1.16 | $21.76M | 17.82M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 98636 | $1.26 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.26 | 600000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 98636 | 1.255 |
6 | 67800 | 1.250 |
2 | 13220 | 1.240 |
2 | 15000 | 1.225 |
2 | 6000 | 1.220 |
Price($) | Vol. | No. |
---|---|---|
1.260 | 600000 | 1 |
1.270 | 5014 | 1 |
1.275 | 13810 | 1 |
1.280 | 6000 | 2 |
1.285 | 40702 | 2 |
Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.27 |
  |
Change
0.105 ( 9.35 %) |
|||
Open | High | Low | Volume | ||
$1.17 | $1.30 | $1.16 | 2142493 | ||
Last updated 15.59pm 28/05/2024 ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online